ADC - Agree Realty Corporation
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lanc
At the 24% federal bracket, a $500,000 portfolio spread evenly across the five monthly payers below throws off roughly $26,130 in gross dividend income a year, and the IRS takes about $6,271 of it if you hold those shares in a taxable brokerage. Inside a Roth, that $6,271 stays yours, every year, reinvested at a... 5 Monthly Dividend Payers That Belong in Your Roth IRA
September has a well-earned reputation as a
Social Security alone leaves most retirees scrambling to cover basic expenses, but a carefully constructed portfolio of five monthly dividend payers could change that equation entirely for Baby Boomers sitting on investable savings.
Capital and Regional (OTCMKTS:CRPLF - Get Free Report) and Agree Realty (NYSE: ADC - Get Free Report) are both real estate companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings. Institutional and Insider Ownership 97.8% of
Agree Realty remains a high-quality net lease REIT, offering an attractive entry point at 17x forward AFFO and a 4% yield. Its fortress balance sheet, A-credit rating, and low leverage (5.2x, or 3.7x including unsettled equity) provide significant financial flexibility. Record investment activity and strong AFFO growth led to raised 2024 guidance, with acquisitions now expected at $1.6–$1.8B and AFFO at $4.57–$4.59.
ADC Therapeutics NYSE: ADCT reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment's commercial performance remained broadly consistent with recent quarters.
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational updates.
Retirees living off portfolio income don't get to sync their grocery bills, utility payments, and Medicare premiums to a quarterly calendar.
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the third quarter of 2025. The dividend is payable September 15, 2026 to stockholder.
Agree Realty (ADC) offers consistent monthly dividends, backed by a resilient, investment-grade tenant base and a strong balance sheet. ADC is not as cheap as it may have been at one time, but based on its forward P/AFFO and ~4% yield, it remains attractive for long-term income investors. The expectation for consistent and continued growth over the long term can continue to fuel those monthly payouts trending in an upward trajectory.
A smaller portfolio built around the right income assets can throw off more cash every year than a million dollars sitting in the S&P 500, but the tradeoffs between each yield tier will determine whether that income grows or quietly erodes.
Agree Realty (NYSE:ADC) and NNN REIT (NYSE:NNN) entered the second half with annualized dividend payout ratios separated by less than half a percentage point.
LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report financial results for the second quarter of 2026 and provide operational updates.
The current market is built around AI. We are seeing more and more signs that the market is getting exhausted by the AI hype. In this setting, I am extra skeptical about high-risk and “too good to be true” yield instruments.
Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company's recently announced strategic research collaboration with WhiteHawk Therapeutics and why the Company believes scientifically driven collaborations will play an increasingly important role in advancing the next generation of ADC innovation.
California State Teachers Retirement System grew its position in shares of Agree Realty Corporation (NYSE: ADC) by 33.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 140,189 shares of the real estate investment trust's stock after buying an additional 35,124
ADC remains a hold due to its high valuation despite outstanding portfolio quality and defensive tenant mix. ADC's portfolio boasts 99.8% occupancy, 66% investment-grade tenants, and leading rent PSF, underpinning its sector outperformance. Recent acquisitions averaged a 7% cap rate with 11.2-year WALT, supporting raised AFFO/share growth guidance to nearly 6% for 2024.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug
Retirees heading into fall want two things from an income portfolio: a check that shows up every 30 days, and a dividend that will not be cut.